Solar FoodsAfter Finnish protein powder producer Solarfoods signed a strategic agreement with two US food manufacturers to supply 6,000 tonnes of Solein from 2030 onwards, the company has now announced a more concrete partnership with US flavour manufacturer Sensapure Flavours Inc.
ECThe European Commission last week unveiled its Life Sciences Strategy, which aims to elevate Europe’s biotechnology sector from third to first place globally by 2030, backed by an investment of €10bn. These funds are to be reallocated to food, agricultural, pharmaceutical and industrial biotechnology sectors.
SandozBiosimilar major Sandoz has started construction of an additional US$440m biosimilar facility near Ljubljana and it set to expand its investment footprint in Slovenia by US$1.1bn.
Unnatural Products IncCalifornia oral macrocyclic peptide specialist Unnatural Products, Inc. and Dutch-Belgian Argenx SE have formed a multi-target research collaboration aimed at developing oral macrocyclic peptide drugs with UNP’s synthetic macrocycle platform.
Vetter Pharma International GmbHCDMO and filled syringe specialist Vetter has broken the ground for a new clinical site construction in the greater Chicago area that is expected to be ready for early clinical filling by the end of 2029.
HeiQ/AeoniQ, RenewcellPortuguese fibre producer Altri SGPS S.A.has signed an agreement to acquire a majority interest in Swiss clean technology company AeoniQ to support the commercial-scale development of the first fully biodegradable cellulose-based filament designed to replace polyester and nylon.
adobe stock photos - Sergii Figurnyi Final negotiations on proposed EU regulations for plants developed through genetic precision breeding have been delayed, following opposition from a group of MEPs in the European Parliament’s ENVI Committee. The group criticised the European Council and the European Commission for their inflexible stance on issues such as sustainability, labelling, and patent protection.
Laverock TherapeuticsBritish targeted gene silencing specialist Laverock Therapeutics Ltd has expanded its seed funding to £20m by a new financing round led by xx and xx. The company said it will use the funds to…l
Medicines for EuropeIn a surprise move, Health Commissioner Oliver Várhelyi announced at the Medicines for Europe Annual Conference that the EU Biotech Act will go ahead this year, reversing its provious delay from Q3 2025 to Q3 2026. The legislation has now been fast-tracked because the Commission recognised biotechnology’s rising geostrategic weight.
www.gov.ukThe UK government has unveiled a new industrial strategy that includes a commitment to invest £380m in engineering biology. The package comprises an initial £196m for research and development, and a further £184m for the expansion and modernisation of pilot and scale-up infrastructure.